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Disease modelinga b s t r a c t
Mitochondrial diseases are heterogeneous disorders, caused by mitochondrial dysfunction.
Mitochondria are not regulated solely by nuclear genomic DNA but by mitochondrial DNA. It is dif-
ﬁcult to develop effective therapies for mitochondrial disease because of the lack of mitochondrial
disease models. Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like epi-
sodes (MELAS) is one of the major mitochondrial diseases. The aim of this study was to generate
MELAS-speciﬁc induced pluripotent stem cells (iPSCs) and to demonstrate that MELAS-iPSCs can
be models for mitochondrial disease. We successfully established iPSCs from the primary MELAS-
ﬁbroblasts carrying 77.7% of m.3243A>G heteroplasmy. MELAS-iPSC lines ranged from 3.6% to
99.4% of m.3243A>G heteroplasmy levels. The enzymatic activities of mitochondrial respiratory
complexes indicated that MELAS-iPSC-derived ﬁbroblasts with high heteroplasmy levels showed a
deﬁciency of complex I activity but MELAS-iPSC-derived ﬁbroblasts with low heteroplasmy levels
showed normal complex I activity. Our data indicate that MELAS-iPSCs can be models for MELAS
but we should carefully select MELAS-iPSCs with appropriate heteroplasmy levels and respiratory
functions for mitochondrial disease modeling.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mitochondrial diseases are genetically and clinically heteroge-
neous disorders, commonly caused by mitochondrial dysfunction
[1,2]. Clinically, they involve multiple tissues although they mainly
affect nervous system, skeletal muscle, and cardiac muscle, all of
which are rich in mitochondria. Each cell in a human body has
thousands of mitochondrial DNA (mtDNA) copies, and theexpression and severity of mitochondrial disease symptoms
depend on the levels of mtDNA mutation-speciﬁc heteroplasmy
(mixture of wild-type and mutated mtDNA) [3].
Mitochondrial myopathy, encephalomyopathy, lactic acidosis,
and stroke-like episodes (MELAS) is one of the major clinical sub-
groups of the mitochondrial diseases and is caused by a single base
replacement in the mtDNA [4]. The majority (80%) of MELAS
patients possess an A to G substitution at mtDNA nucleotide posi-
tion 3243, denoted as m.3243A>G [5]. MELAS presents a broad
clinical spectrum involving seizures, stroke-like episodes, mental
disorders, sensorineural deafness, progressive muscle weakness,
cardiomyopathy, and other organ symptoms. The estimated
threshold proportion of m.3243A>G heteroplasmy sufﬁcient to
impair mitochondrial respiratory function in MELAS is 90% in cel-
lular systems [6] and 70% in muscle ﬁbers [7]. Accumulating evi-
dences help us understand the pathogenesis, but there is no
effective therapy for mitochondrial diseases. Available treatments
serve only to alleviate symptoms and slightly delay disease
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ments are complicated due to the rarity of patients with mitochon-
drial disease and the lack of disease models. Transmitochondrial
cybrid cell lines have been used as artiﬁcial mitochondrial disease
models to identify relationships between the proportion of mutant
mtDNA and impaired biochemical functions in mitochondria [8,9].
However, human cell models are needed to sufﬁciently understand
the cellular pathophysiology in various mitochondrial diseases.
The generation of induced pluripotent stem cells (iPSCs) from
patients with genetic disorders holds enormous promise for under-
standing the pathogenesis of complex diseases [10,11]. Speciﬁcally,
disease-speciﬁc iPSCs have opened new possibilities for generating
continuous supplies of human diseased cells for basic research and
drug screening. Most genetic diseases are affected by genomic DNA
mutation but mitochondrial diseases are mostly affected by
mtDNA mutation. It remains unknown whether mitochondrial dis-
ease model could also be generated by patient-speciﬁc iPSCs. The
present study sought to demonstrate the generation of disease-
speciﬁc iPSCs from a patient with MELAS carrying m.3243A>G
heteroplasmy for disease modeling. We also evaluated the
mitochondrial genotype-phenotype correlation between mtDNA
heteroplasmy and the mitochondrial oxidative phosphorylation
system (OXPHOS).
2. Materials and methods
2.1. Human iPSC generation
The iPSCs were established as described previously [11], using
lentiviral vectors to introduce mouse solute carrier family 7, a
member 1 (Slc7a1) gene encoding the ecotropic retrovirus recep-
tor. Transfectants were plated at 2  105 cells per 60-mm dish,
and the next day, OCT4, SOX2, KLF4, and MYC were introduced
by retroviral transduction. After another 24 h, the virus-containing
mediumwas aspirated and the cell culture continued under ﬁbrob-
last conditions. Thereafter those cells were cultured under iPSC
culture condition. Six days later, the cells were harvested and pla-
ted at 5  104 cells per 100-mm dish for another 20 days of cultur-
ing. At day 25, embryonic stem (ES) cell-like colonies were
mechanically dissociated and transferred to a 24-well plate con-
taining adhered mouse embryonic ﬁbroblast (MEF) feeder cells.
The isolation and use of patient somatic cells was approved by
the Institutional Review Board, NCNP (21-9-10) and the Ethics
Committee of Keio University (approval No. 20-92-5), and con-
ducted under the Declaration of Helsinki. Patient information
was encoded to protect privacy, and written informed consent
obtained. The MELAS-iPSC line was maintained in the undifferenti-
ated state on irradiated MEF feeder cells in DMEM/F12 medium
(Invitrogen, CA, USA) supplemented with 20% Knock-out Serum
Replacement (KSR) (Invitrogen), 1 mM L-glutamine (Invitrogen),
1 mM nonessential amino acids (Sigma–Aldrich, MO, USA),
0.1 mM b-mercaptoethanol, and 4 ng/ml basic ﬁbroblast growth
factor (bFGF). The iPSC culture medium was changed daily, and
the cells were passaged every 5–6 days. We generated iPSCs from
donor MELAS-ﬁbroblasts multiple times and named iPSC clone in
same dish as same alphabet.
2.2. Teratoma formation
To conﬁrm pluripotency in vivo, teratoma formation was
assessed in accordance with the Institutional Animal Care and
Use Committee of Keio University. Approximately 1–2  106 iPSCs
were injected into the testis of anesthetized immune-compromised
NOD-SCID mice (CREA-Japan, Tokyo, Japan). At 10–12 weeks after
the injection, mice were euthanized and the teratomas were
excised, ﬁxed overnight in formalin, embedded in parafﬁn, andanalyzed by haematoxylin-eosin staining [12]. The mice were anes-
thetized using a mixture of ketamine (50 mg/kg), xylazine (10 mg/
kg), and chlorpromazine (1.25 mg/kg). The adequacy of anesthesia
wasmonitored by heart rate, muscle relaxation, and the loss of sen-
sory reﬂex responses, i.e., nonresponsive to tail pinching. The
investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (publications number 23–80 revised in 2011).
2.3. Immunoﬂuorescence
The immunostaining was performed using the following
primary antibodies and reagents: anti-OCT4 (sc-5279, Santa Cruz,
CA, USA), anti-NANOG (RCAB0003P, ReproCELL, Yokohama,
Japan), anti-SSEA 4 (MAB4304, Millipore), anti-Tra1-60
(MAB4360, Millipore, MA, USA), anti-human smooth muscle actin
monoclonal antibody (Agilent Technologies, CA, USA), goat anti-hu-
man SOX17 polyclonal antibody (R&D Systems, MN, USA), rabbit
anti-Nestin polyclonal antibody (Sigma), or Prolyl 4-hydroxylase
beta (PH4B) (Acris Antibodies GmbH, Herford, Germany), together
with 40,60-diamidino-2-phenylindole (DAPI; ThermoFisher
SCIENTIFIC, MA, USA) [13]. Signal was detected using a conven-
tional ﬂuorescence laser microscope (BZ-9000, KEYENCE, Osaka,
Japan) equipped with a color charge-coupled device camera
(BZ-9000, KEYENCE).
2.4. mtDNA mutation analysis
Mutation ratios of m.3243A>G were determined as follows.
Extracted DNA (1 ng) was used for quantitative PCR with the
TaqMan Universal PCR Master Mix kit (ThermoFisher SCIENTIFIC)
according to the manufacturer’s instructions. A sequence detection
system (ABI PRISM 7900HT; Applied Biosystems) was used, and a
calibration curve was created using several known copy numbers
of plasmid containing the ampliﬁed mtDNA fragments for either
wild-type or mutant sequences. Primers and allele-speciﬁc
TaqMan probes used were as follows: forward primer (50-CCACCC
AAGAACAGGGTTTG-30), reverse primer (50-GGAATTGAACCTCTGA
CTGTAAAGTTT-30), wild-type allele-speciﬁc TaqMan probe (50-
AGATGGCAGAGCCCGGTA-30; with VIC-ﬂuorogenic probe at the 50
terminus), mutant allele-speciﬁc TaqMan probe (50-AGATGGCAG
GGCCCGGTA-30; with FAM-ﬂuorogenic probe at the 50 terminus).
2.5. mtDNA copy number analysis
mtDNA copy number was determined as follows. Extracted
DNA (1 ng) was used as template for quantitative PCR with
Power SYBR Green PCR Master Mix kit (ThermoFisher
SCIENTIFIC) according to the manufacturer’s instructions. A
Sequence detection system (ABI PRISM 7900HT; Applied
Biosystems) was used, and the threshold cycle number for
mtDNA gene (MT-CYB) and for nuclear DNA gene (FBXO15) were
adopted for DDCt-based relative quantiﬁcation. Primers used were
as follows: MT-CYB forward primer (50-TGCAACTATAGCAACAGCCT
TCA-30),MT-CYB reverse primer (50-GAACTAGGTCTGTCCCAATGTAT
GG-30), FBXO15 forward primer (50-GCCAGGAGGTCTTCGCTGTA-30),
FBXO15 reverse primer (50-AATGCACGGCTAGGGTCAAA-30).
2.6. In vitro differentiation
iPSCs were harvested using 1 mg/ml collagenase IV (Invitrogen),
and then colonies were transferred to ultralow attachment plates
(Corning, NY, USA) in iPSC culture medium without bFGF. After
8 days, aggregated cells (embryoidbody (EB))wereplatedontogela-
tin-coated tissue culture dishes. The cells were incubated at 37 C in
5%CO2 and themediumwas replaced every other day for 8–10 days.
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Cells were harvested using 1 mg/ml collagenase IV (Invitrogen),
and then transferred toultra-lowattachment plates (Corning) in dif-
ferentiation medium (DMEM/F12 supplemented with 20% FBS,
1 mM L-glutamine, 1 mM nonessential amino acids, and 0.1 mM b-
mercaptoethanol), as described previously [11]. The EBs were incu-
bated at 37 C in 5% CO2, and the medium was replaced every 3–
4 days for 8–10 days. EBswere plated onto gelatin-coated tissue cul-
ture dishes. After 7–10 days, differentiated ﬁbroblast-like cellswere
seen and these were expanded by culturing in DMEMmediumwith
10% FBS and serially passaged with trypsin for at least six passages.
2.8. Cell growth
20 wells of a 24 well tissue culture plate with MEF feeder cells
were seeded with approximately 20,000 iPSCs/well. 24 h later, 4
wells of MEF feeder cells and 4 wells of iPSCs with MEF feeder cells
were trypsinized to a single cell suspension and counted. The eight
counts for the MEF feeder cells were averaged and subtracted from
the average of the eight counts that corresponded to those wells
with iPSCs. This value was used as a baseline (Day 0) for the dou-
bling time assay. This procedure was repeated with 4 wells of iPSCs
in the condition of regular iPSC culture.
2.9. Chromosome karyotyping
iPSCs treated with colcemid solution (60 ng/ml) were cultured
for 5 h at 37 C to stop cell growth in metaphase. These cells were
then incubated in 0.075 M KCl solution for 10 min at room tem-
perature, followed by ﬁxation in Carnoy’s solution. Fixed cells were
sent to Nihon Gene Research Laboratories Inc. (Sendai, Japan) for
analysis.
2.10. Mitochondorial enzymatic activity measurement
Enzymatic activities for mitochondrial respiratory complexes
were analyzed as described elsewhere [14] with modiﬁcations. In
brief, after culturing the harvested cells were resuspended in isola-
tion buffer (pH 7.4) containing 210 mM mannitol, 70 mM sucrose,
1 mM EGTA, and 5 mM HEPES, and then homogenized on ice. Cell
lysates were centrifuged to isolate mitochondrial proteins, which
were quantiﬁed by Bradford assay, with a calibration curve created
using several known concentrations of BSA. All samples were mea-
sured in triplicate using a spectrophotometric multi-well plate
reader (SPECTROstar Nano; BMG Labtech). Citrate synthase (CS)
activity was used for normalization of respiratory complexes
activities in each sample. For measuring complex I activity, reac-
tion buffer (pH 7.4; containing 50 mM Tris–HCl, 250 mM sucrose,
1 mM EDTA, 5 lg/ml antimycin A, 2 mM KCN, 10 lM decylubiqui-
none (DQ), and 50 lM NADH) was added and the mixture was
incubated at 37 C. Isolated mitochondrial proteins (1 lg) were
then added to monitor the time-dependent spectrum alterations
at 340 nm. For complex II activity, reaction buffer (pH 7.4;
containing 50 mM potassium phosphate, 5 lg/ml rotenone,
5 lg/ml antimycin A, 2 mM KCN, 20 mM succinate, 50 lM 2,6-
dichlorophenolindophenol (DCPIP), and 50 lM DQ) was added
and the mixture was incubated at 37 C. Isolated mitochondrial
proteins (1 lg) were then added to monitor the time-dependent
spectrum alterations at 600 nm. For complex III activity, reaction
buffer (pH 7.4; containing 50 mM Tris–HCl, 250 mM sucrose,
1 mM EDTA, 2 mM KCN, 50 lM cytochrome c, and 50 lM decylubi-
quinol [reduced form of DQ]) was added and the mixture was
incubated at 37 C. Isolated mitochondrial proteins (1 lg) were
then added to monitor the time-dependent spectrum alterations
at 550 nm. For complex IV activity, reaction buffer (pH 7.4;containing 10 mM potassium phosphate and 25 lM ferrocy-
tochrome c [reduced form of cytochrome c]) was added and the
mixture was incubated at 37 C. Isolated mitochondrial proteins
(1 lg) were then added to monitor the time-dependent spectrum
alterations at 550 nm. For citrate synthase activity, reaction buffer
(pH 8.0; containing 125 mM Tris–HCl, 300 lM acetyl-CoA, 100 lM
5,50-dithiobis [2-nitrobenzoic acid] (DTNB), and 500 lM oxaloac-
etate) was added and the mixture was incubated at 37 C.
Isolated mitochondrial proteins (1 lg) were then added to monitor
the time-dependent spectrum alterations at 415 nm.
2.11. Statistical analysis
All results are expressed as mean ± SD of three independent
experiments. The measurements were statistically analyzed using
Student’s t-test for comparing two groups.
3. Results
3.1. iPSC generation from a patient with MELAS
Primary ﬁbroblasts were derived from skin biopsy samples from
a MELAS patient. The primary MELAS ﬁbroblasts carrying 77.7% of
m.3243A>G. Retroviral vectors carrying OCT4, SOX2, KLF4, andMYC
were infected into those ﬁbroblasts. After 3–4 weeks, compact
embryonic stem (ES)-cell-like colonies emerged, and these were
clonally expanded to create 20 stable iPSC lines. All iPSC clones
expressed pluripotent markers OCT4, Tra1-60, NANOG, and
SSEA4 (Fig. 1A). We also conﬁrmed the in vitro differentiation
capability of these MELAS-iPSCs. Embryoid bodies (EBs) were gen-
erated from each MELAS-iPSC line and plated on gelatin-coated
dishes on day 7. A few days later, the EBs were immunostained
for Nestin (ectoderm marker), aSMA (mesoderm marker), and
SOX17 (endoderm marker). Each iPSC lines tested similarly gener-
ated EBs and contained derivatives of all three germ layers
(Fig. 1B). Next we examined the multipotency of MELAS-iPSC,
based on teratoma formation which involved tissues derived from
all three germ layers (Fig. 1C). Karyotype and growth rate are also
examined in representative MELAS-iPSC lines (Fig. 1D and E).
3.2. The variation of mitochondria heteroplasmy in MELAS-iPSCs
By quantitative real-time PCR, the m.3243A>G heteroplasmy
levels in MELAS-iPSC lines ranged from 3.6% (line D1) to 99.4% (line
G1), and 14 MELAS-iPSC lines had a mutant heteroplasmy level of
over 80% (Fig. 2). These results indicated that MELAS-iPSC lines
with a wide variety of m.3243A>G contents (<5% to >95%) could
be established from the same patient. Nevertheless, those
MELAS-iPSC lines showed typical iPSC morphology (Fig. 1A), dif-
ferentiation capability into three different germ layer-derived tis-
sues (Fig. 1B and C) and typical growth rates of human iPSCs
(Fig. 1E). During reprogramming of the ﬁbroblasts to iPSCs,
mitochondria assumed an apparently ‘‘quiescent’’ state: a round-
shaped morphology with poor cristae structure, less active
OXPHOS, and reduced mtDNA copies [15]. Undifferentiated human
iPSCs predominantly produce energy by anaerobic glycolysis, and
this could explain why MELAS-iPSC lines carrying a higher propor-
tion of m.3243A>G, even over its pathogenic threshold level, were
also stably established.
3.3. Maintenance of heteroplasmy levels after long-term culture and
ﬁbroblast differentiation
To examine the inﬂuences of long-term iPSC culture on
m.3243A>G content, we compared m.3243A>G heteroplasmy
levels between cells from passage 10 and passage 40 using ﬁfteen
Fig. 1. (A) Immunostaining for pluripotency and surface markers (NANOG, OCT4, SSEA4, and Tra1-60) in representative MELAS-iPSCs (H1, M2, and K2). Scale bars represent
500 lm. (B) Immunoﬂuorescence staining for Nestin (ectodermal marker), aSMA (mesodermal marker), and Sox17 (endodermal marker) in representative MELAS-iPSC-
derived differentiated cells (H1, M2, and K2). (C) Microscopic observation of teratoma sections in representative MELAS-iPSCs (H1, M2, and K2), showing tissue structures
resembling gut (endoderm), cartilage (mesoderm), adipose (mesoderm), and neural tissue (ectoderm). (D) Normal karyotype of representative MELAS-iPSCs (M2). (E) Cell
growth curves of representative MELAS-iPSCs (H1, M2, and K2).
Fig. 2. Histogram of the number of MELAS-iPSC lines with different heteroplasmy
levels.
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long-term culture in iPSC with low heteroplasmy levels (C1 and
K2) (Fig. 3A). But no apparent differences in m.3243A>G hetero-
plasmy levels were observed among iPSC with high heteroplasmy
levels after long-term culture (Fig. 3A). We also examined the
mtDNA copy number between cells from passage 10 and passage
40 using eleven MELAS-iPSC lines, which showed that mtDNA copy
numbers dynamically changed after passage (Fig. 3B). We didn’t
observe the relation between the iPSC clones with high hetero-
plasmy and those with low heteroplasmy. Next we asked if the
level of heteroplasmy could be maintained during differentiation
of the MELAS-iPSCs into ﬁbroblasts. Ten MELAS-iPSC lines were
enzymatically harvested and transferred to be cultured on low
attachment dishes with the differentiation medium to form EBs.
EBs were plated on gelatin-coated dishes at day 7. After ﬁve
passages, the EBs differentiated to uniform ﬁbroblasts (Fig. 3C).
The purities of ﬁbroblasts were approximately over 95%.
Interestingly, evaluation of the change in m.3243A>G hetero-
plasmy levels upon differentiation by quantitative real-time PCR
measurements revealed that the heteroplasmy levels were similar
after ﬁbroblast differentiation in each MELS-iPSC line (Fig. 3D).
Fig. 3. (A) Heteroplasmy levels in 15 MELAS-iPSC lines at passage 10 and 40. (B) mtDNA/nuclearDNA (nDNA) copy number in 11 MELAS-iPSC lines at passage 10 and 40. (C)
Immunostaining for ﬁbroblast marker (P4HB) in representative MELAS-iPSC-derived ﬁbroblasts. (D) Heteroplasmy levels in 10 MELAS-iPSC lines and iPSC-derived ﬁbroblasts.
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MELAS-iPSC derived ﬁbroblasts
To further characterize the potential for disease modeling, we
examined the enzymatic activities of mitochondrial respiratory
complexes I, II, III, and IV in MELAS-iPSC-differentiated ﬁbroblasts
from the four MELAS-iPSC lines (K1, H1, C11, and M2) and in pri-
mary skin ﬁbroblasts derived from a donor patient, and compared
them with skin ﬁbroblasts of ten healthy persons (normalized as
100%). Enzymatic activities for mitochondrial respiratory
complexes were analyzed as described elsewhere [14] with mod-
iﬁcations. Mitochondrial heteroplasmy levels at the time of enzy-
matic analysis in the donor and iPSC-derived ﬁbroblasts (K1, H1,
C11, and M2) were 75%, 64%, 70%, 81%, and 100%, respectively.
To normalize for content of mitochondria, each enzymatic activity
was normalized against citrate synthase (CS) activity (Fig. 4A) andcomplex II (Fig. 4B) [16]. The complex II is regulated not by mtDNA
but by nuclear DNA. The difference in the complex II would not be
directly affected by mtDNA mutation. The normalization by com-
plex II can minimize the effect of mitochondrial DNA mutation.
The enzymatic activities of complex I were decreased in MELAS-
iPSC lines H1, C11, and M2, and in the MELAS-donor ﬁbroblasts
(Fig. 4A and B). However, no decrease in enzymatic activity was
observed for complexes II, III, and IV in the MELAS-iPSC-derived
ﬁbroblasts, despite the possibility that these complexes might be
induced by the overall tRNA functional defect. In MELAS patients,
complex I deﬁciency is the most common feature of mitochondrial
enzymatic activity. A defect in the taurine modiﬁcation of mutant
tRNALeu(UUR) causes reduction in mitochondrial translation of the
ND6 gene, which encodes a component of respiratory chain com-
plex I. On the contrary, complexes II, III, and IV are not affected
in MELAS patients [17]. Complexes II and IV normalized against
Fig. 4. Enzymatic activity analysis for mitochondrial respiratory complexes in healthy-ﬁbroblasts, donor MELAS-ﬁbroblasts and 4 MELAS-iPSC-derived ﬁbroblasts,
normalized against citrate synthase (CS) activity (A) and complex II (B).
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functional complementation for the decreased activity of complex
I, but complex IV normalized against complex II didn’t show sig-
niﬁcant difference (Fig. 4B). These results indicate that the patho-
genic threshold levels of m.3243A>G were recapitulated in
MELAS-iPSC-derived ﬁbroblasts from a donor patient.
4. Discussion
In this study, we successfully generated disease-speciﬁc iPSCs
from a MELAS patient carrying m.3243A>G heteroplasmy, and
our MELAS-iPSC lines showed a wide range of m.3243A>G content
(<5% to >95%) suitable for possible applications in disease model-
ing and drug screening. Mitochondria is the only organelle which
contains their own DNA besides the nuclear DNA in mammals.
Mitochondrial DNA is exclusively maternally transmitted during
mammalian fertilization. mtDNA can expand clonally during
mtDNA replication in somatic cells and mtDNA mutation would
randomly segregate during cell division and result in daughter cells
that exhibit low or high levels of heteroplasmy in somatic cells
[18]. In this study, we examined the levels of heteroplasmy of
mtDNA during reprogramming, iPSC maintenance and iPSC dif-
ferentiation, and the enzymatic activities of mitochondrial respira-
tory complexes in iPSC-derived ﬁbroblasts.
Disease modeling using disease-speciﬁc iPSCs will shed light on
the unknown disease pathogenesis and drug screening.
Speciﬁcally, patient-speciﬁc iPSCs harboring m.3243A>G were
recently generated from two diabetic patients [19] and examined
for m.3243A>G content, but not mitochondrial function. In that
study, the parent ﬁbroblasts contained small amounts of mutated
mtDNA. Disease-speciﬁc iPSCs carrying different mutant mtDNAs
have also been reported: m.13513G>A and a 2501 base-pair dele-
tion in mtDNA [20,21]. Those reports mostly argued about hetero-
plasmy levels and cellular phenotypes such as cell growth and
differentiation ability. Another recent report also showed thegeneration of MELAS-iPSCs harboring m.3243A>G [22]. They
showed the expression of mtDNA encoded genes related to
mitochondrial respiratory complexes I was decreased in MELAS-
iPSC derived neurons. Mitochondrial diseases can be critically
manifested by mitochondrial function and are heterogenic disor-
ders partly due to the proportion of mtDNA mutation and/or abso-
lute number of mtDNA copies. In terms of mitochondrial disease
modeling, we have to carefully evaluate both heteroplasmy levels
in iPSCs and mitochondrial function. Our patient-derived MELAS-
iPSCs carrying a range of m.3243A>G levels could therefore serve
as cellular disease models for facilitating mitochondrial medicine.
Cell replacement therapy for diseased organs is one of the
attractive applications of patient-speciﬁc iPSCs, although such
therapy could be problematic for mitochondrial disease due to
the multiple organs affected. Speciﬁc organs such as skeletal mus-
cle, heart, and nervous system, were seriously affected in many
cases. However, the scarcity of therapeutic options thus far for
these patients also raises the potential value of cell replacement
therapy. In our study, we demonstrate that some MELAS-iPSC lines
have extremely low levels of heteroplasmy, meaning that we can
obtain isogenic iPSCs with normal mitochondrial respiratory func-
tion from the one patient. This indicates the potential for future
therapeutic applications in mitochondrial diseases without genetic
correction by using these isogenic iPSC-derived target cell types in
autologous cell replacement therapy without concern about
immunological rejection.Author contributions
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